Startseite>>Signaling Pathways>> Neuroscience>> COX>>SC57666

SC57666

Katalog-Nr.GC31960

SC57666 ist ein selektiver COX2-Hemmer mit einem IC50 von 26 nM.

Products are for research use only. Not for human use. We do not sell to patients.

SC57666 Chemische Struktur

Cas No.: 158959-32-1

Größe Preis Lagerbestand Menge
1mg
252,00 $
Auf Lager
5mg
504,00 $
Auf Lager
10mg
855,00 $
Auf Lager
20mg
1.575,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SC57666 is a selective COX2 inhibitor with an IC50 of 26 nM.

SC57666 inhibits COX2 with an IC50 of 3.2±0.8 nM in CHO cells stably transfected with human COX isozymes, with 1000 fold or more selectivity over COX1 (IC50=6000±1900 nM)[2].

SC57666 has been shown to be orally active (ED50=1.7 mpk) in the adjuvant-induced arthritis model. No gastric lesions are observed in mice after 5 h when SC57666 is administered intragastrically at 600 mpk. No intestinal damage is observed in rats after 72 h when SC57666 is administered intragastrically at 200 mpk[1].

[1]. Reitz DB, et al. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally activeCOX2 inhibitors. J Med Chem. 1994 Nov 11;37(23):3878-81. [2]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.

Bewertungen

Review for SC57666

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SC57666

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.